ABLE-32: A randomized, controlled, phase 3b clinical trial of nadofaragene firadenovec-vncg versus observation in patients with intermediate-risk non–muscle-invasive bladder cancer.
Authors
Mark Douglas Tyson (ORCID: https://orcid.org/0009-0001-5346-1404)
Trinity Bivalacqua
Michael B. Williams (ORCID: https://orcid.org/0000-0003-0836-2455)
Per Sandström (ORCID: https://orcid.org/0000-0002-8078-9528)
Corine Baayen
Vikram M. Narayan (ORCID: https://orcid.org/0000-0003-3731-4209)
Gautum Agarwal
Neal D. Shore (ORCID: https://orcid.org/0000-0001-5767-0548)
Kristian Vinter Juul (ORCID: https://orcid.org/0000-0002-2233-1746)
ABLE-32: A randomized, controlled, phase 3b clinical trial of nadofaragene firadenovec-vncg versus observation in patients with intermediate-risk non–muscle-invasive bladder cancer.
Mark Douglas Tyson, Trinity Bivalacqua, Michael B. Williams, Per Sandström et al.
Journal
Journal of Clinical Oncology
Topics
Bladder and Urothelial Cancer Treatments
article
ABLE-32: A randomized, controlled, phase 3b clinical trial of nadofaragene firadenovec-vncg versus observation in patients with intermediate-risk non–muscle-invasive bladder cancer.
Mark Douglas Tyson, Trinity Bivalacqua, Michael B. Williams, Per Sandström, Corine Baayen, Vikram M. Narayan, Gautum Agarwal, Neal D. Shore, Kristian Vinter Juul, Evan R. Goldfischer, Rian J. Dickstein
article en
Abstract
No abstract available for this paper.
Publication Tag
Journal of Clinical OncologyVol. 43(5_suppl)
Institutions
University of Maryland, Baltimore (US), Emory University (US), Eastern Virginia Medical School (US), Hospital of the University of Pennsylvania (US), Urology of Virginia (US), Mayo Clinic Hospital (US), Ferring Pharmaceuticals (Denmark) (DK), Carolina Urologic Research Center (US)
Ask Laika to Summarize, Analyze, and Connect papers live on the map.
Summarize Papers & Methodologies
Extract key findings, datasets, and comparative methods across publications.
Benchmark Rankings & Visual Analytics
Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.
Connect Distant Disciplines
Bridge topological clusters on the map to find hidden collaborative intersections.
ABLE-32: A randomized, controlled, phase 3b clinical trial of nadofaragene firadenovec-vncg versus observation in patients with intermediate-risk non–muscle-invasive bladder cancer. — Mark Douglas Tyson, Trinity Bivalacqua, et al. · Journal of Clinical Oncology (2025) | TGRS Research Map | TGRS